We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+8.32%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$520M
AUM Growth
+$42.5M
Cap. Flow
+$27.3M
Cap. Flow %
5.25%
Top 10 Hldgs %
74.31%
Holding
43
New
3
Increased
1
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$39.6M
2
ARTV
Artiva Biotherapeutics
ARTV
+$3.38M
3
JSPR icon
Jasper Therapeutics
JSPR
+$1.19M
4
BCAX
Bicara Therapeutics
BCAX
+$893K

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$6.66M
2
CLYM
Climb Bio
CLYM
+$4.61M
3
VRNA
Verona Pharma
VRNA
+$3.75M
4
IGMS
IGM Biosciences
IGMS
+$1.06M
5
JANX icon
Janux Therapeutics
JANX
+$980K

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTVT icon
26
vTv Therapeutics
VTVT
$139M
$2.81M 0.54%
206,784
– –
IMTX icon
27
Immatics
IMTX
$1.32B
$2.26M 0.43%
198,000
– –
PRME icon
28
Prime Medicine
PRME
$559M
$2.09M 0.4%
540,304
– –
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
$2.05M 0.39%
147,319
-49,106
-25% -$701K
TERN
30
DELISTED
Terns Pharmaceuticals
TERN
$1.69M 0.32%
202,348
– –
HLVX
31
DELISTED
HilleVax
HLVX
$1.41M 0.27%
799,274
– –
JANX icon
32
Janux Therapeutics
JANX
$967M
$1.02M 0.2%
22,526
-22,526
-50% -$980K
BCAX
33
Bicara Therapeutics
BCAX
$1.84B
$891K 0.17%
+35,000
New +$893K
ACRS icon
34
Aclaris Therapeutics
ACRS
$869M
$801K 0.15%
696,171
– –
LYRA
35
DELISTED
LYRA THERAPEUTICS INC
LYRA
$715K 0.14%
55,605
– –
BOLT icon
36
Bolt Biotherapeutics
BOLT
$7.78M
$680K 0.13%
52,458
– –
VIRX
37
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$160K 0.03%
689,709
– –
ALLK
38
DELISTED
Allakos
ALLK
$112K 0.02%
172,089
– –
KRON
39
DELISTED
Kronos Bio
KRON
$78.1K 0.02%
78,131
– –
KLRS
40
Kalaris Therapeutics
KLRS
$96.8M
$66.6K 0.01%
3,580
– –
NUVB.WS
41
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.1K ﹤0.01%
133,333
– –
SRZNW icon
42
Surrozen Inc Warrant
SRZNW
$8.86K
$1.03K ﹤0.01%
99,999
– –
IGMS
43
DELISTED
IGM Biosciences
IGMS
– –
-154,664
Closed -$1.06M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2024 Portfolio in Review

As of Q3 2024, Samsara BioCapital held 43 positions worth $520M, up 8.9% from $478M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Samsara BioCapital deployed $27.3M of net new capital in Q3 2024, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Alumis Inc: 3,266,498 shares worth $34.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $6.66M trimmed.

  • Samsara BioCapital's largest Q3 2024 buy was Alumis Inc: 3,266,498 shares worth $34.9M.
  • Samsara BioCapital added most to Jasper Therapeutics in Q3 2024, an estimated $1.19M increase.
  • Samsara BioCapital's biggest Q3 2024 reduction was Arcellx, cutting an estimated $6.66M.
  • Samsara BioCapital fully exited IGM Biosciences in Q3 2024, selling an estimated $1.06M.
  • Samsara BioCapital's ten largest holdings make up 74% of its $520M portfolio in Q3 2024.
  • Samsara BioCapital opened 3 new positions and closed 1 in Q3 2024.
  • Samsara BioCapital's portfolio value rose 8.9% quarter-over-quarter to $520M.

Based on Samsara BioCapital's 13F filing for Q3 2024, filed 14 Nov 2024.